Johnson & Johnson Market Cap 2012-2025 | JNJ

Johnson & Johnson market cap history and chart from 2012 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Johnson & Johnson market cap as of April 10, 2026 is $586.69B.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $586.690B $94.193B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $981.092B 42.96
AbbVie (ABBV) United States $409.150B 23.15
Roche Holding AG (RHHBY) Switzerland $372.740B 0.00
Novartis AG (NVS) Switzerland $344.536B 18.16
Merck (MRK) United States $301.342B 13.53
Novo Nordisk (NVO) Denmark $221.330B 12.68
Pfizer (PFE) United States $156.812B 8.54
Sanofi (SNY) France $112.219B 10.39
Bayer (BAYRY) Germany $53.369B 9.37
Innoviva (INVA) United States $1.697B 8.50